- Overview
- Properties
- Related Genes
- Pathways
- Related Drugs
- Related Diseases
- Datasets
- Downloads/LinkOuts
Overview
| Generic Names: | Quinidine Gluconate; Quinidine Sulfate |
|---|---|
| Trade Names: | Apo-Quinidine; Biquin Durules; Cardioquin; Chinidin; Cin-Quin; Coccinine; Conchinin; Conchinine; Conquinine; Duraquin; Kinidin; Novoquinidin; Pitayin; Pitayine; Quin-Release; Quinact; Quinaglute; Quinaglute Dura-Tabs; Quinalan; Quinate; Quinatime; Quindine; Quinicardine; Quinidex; Quinidex Extentabs; Quinora |
| PharmGKB Accession Id: | PA451209 |
Description
An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. PubChem (source: Drug Bank)
Indication
For the treatment of ventricular pre-excitation and cardiac dysrhythmias (source: Drug Bank)
ATC Therapeutic Category
- C01BA:Antiarrhythmics, class Ia
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Quinidine acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. (source: Drug Bank)
Pharmacology
Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation. (source: Drug Bank)
Food Interactions
Preferably take on an ampty stomach. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Protein Binding
80-88% (source: Drug Bank)
Isomeric SMILES Code:
COc1ccc2c(c1)c(ccn2)[C@@H]([C@@H]3CC4CCN3C[C@H]4C=C)O (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
|
ABCB1 |
|
Publications |
|
|
CYP2D6 |
|
Publications |
|
|
CYP3A4 |
|
Publications |
|
|
KCNH2 |
|
Publications |
|
|
SLC6A12 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ABCB1 |
|
(source: Drug Bank) |
| ORM1 |
|
(source: Drug Bank) |
| KCNK1 |
|
(source: Drug Bank) |
| KCNK6 |
|
(source: Drug Bank) |
| KCNH2 |
|
(source: Drug Bank) |
| SCN5A |
|
(source: Drug Bank) |
PharmGKB Curated Pathways
The following drugs are in curated knowledge about this drug.
| Drug | Relationship | Evidence | |
|---|---|---|---|
|
|
donepezil |
|
Publications |
|
|
galantamine |
|
Publications |
|
|
hydrocodone |
|
Publications |
|
|
tamoxifen |
|
Publications |
|
|
warfarin |
|
Publications |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| acenocoumarol |
|
Quinine/quinidine increases the anticoagulant effect (source: Drug Bank) |
| amiloride |
|
Amiloride decreases the antiarrhythmic effect of quinidine (source: Drug Bank) |
| amiodarone |
|
Amiodarone increases the effect of quinidine (source: Drug Bank) |
| amitriptyline |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| amobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| anisindione |
|
Quinine/quinidine increases the anticoagulant effect (source: Drug Bank) |
| aprobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| aripiprazole |
|
Quinidine increases the effect and toxicity of aripiprazole (source: Drug Bank) |
| atazanavir |
|
Increased risk of cardiotoxicity/arrhythmias (source: Drug Bank) |
| atomoxetine |
|
The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank) |
| atracurium |
|
The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank) |
| butabarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| butalbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| butethal |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| cimetidine |
|
Cimetidine increases the effect of quinidine (source: Drug Bank) |
| cisapride |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| clarithromycin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| clomipramine |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| codeine |
|
Quinidine decreases the analgesic effect of codeine (source: Drug Bank) |
| desipramine |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| dextromethorphan |
|
Quinidine increases the toxicity of dextromethorphan (source: Drug Bank) |
| dicumarol |
|
Quinine/quinidine increases the anticoagulant effect (source: Drug Bank) |
| digitoxin |
|
Quinine/quinidine increases the effect of digoxin (source: Drug Bank) |
| digoxin |
|
Quinine/quinidine increases the effect of digoxin (source: Drug Bank) |
| diltiazem |
|
Diltiazem increases the effect and toxicity of quinidine (source: Drug Bank) |
| donepezil |
|
Possible antagonism of action (source: Drug Bank) |
| doxepin |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| erythromycin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| fosphenytoin |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| galantamine |
|
Possible antagonism of action (source: Drug Bank) |
| gallamine triethiodide |
|
The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank) |
| gatifloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| grepafloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| heptabarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| hexobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| imipramine |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| itraconazole |
|
The imidazole increases the effect and toxicity of quinidine (source: Drug Bank) |
| ketoconazole |
|
The imidazole increases the effect and toxicity of quinidine (source: Drug Bank) |
| levofloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| magnesium |
|
The antacid increases the effect of quinidine (source: Drug Bank) |
| mesoridazine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| methohexital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| methylphenobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| metocurine |
|
The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank) |
| moxifloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| nelfinavir |
|
Nelfinavir increases the effect and toxicity of quinidine (source: Drug Bank) |
| nifedipine |
|
Decreased quinidine effect, increased nifedipine effect (source: Drug Bank) |
| nortriptyline |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| ofloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| pancuronium |
|
The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank) |
| pentobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| phenobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| phenytoin |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| posaconazole |
|
Contraindicated co-administration (source: Drug Bank) |
| primidone |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| procainamide |
|
Quinidine increases the effect of procainamide (source: Drug Bank) |
| propafenone |
|
Quinidine increases the effect of propafenone (source: Drug Bank) |
| protriptyline |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| quinidine |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| quinupristin |
|
This combination presents an increased risk of toxicity (source: Drug Bank) |
| ranolazine |
|
Possible additive effect on QT prolongation (source: Drug Bank) |
| rifampin |
|
Rifampin decreases the effect of quinidine (source: Drug Bank) |
| ritonavir |
|
Ritonavir increases the effect and toxicity of quinidine (source: Drug Bank) |
| rivastigmine |
|
Possible antagonism of action (source: Drug Bank) |
| salicylate-magnesium |
|
The antacid increases the effect of quinidine (source: Drug Bank) |
| secobarbital |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| sodium |
|
The antacid increases the effect of quinidine (source: Drug Bank) |
| sodium bicarbonate |
|
The antacid increases the effect of quinidine (source: Drug Bank) |
| sparfloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| succinylcholine |
|
The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank) |
| talbutal |
|
The anticonvulsant decreases the effect of quinidine (source: Drug Bank) |
| telithromycin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| terfenadine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| thioridazine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| trimipramine |
|
Quinidine increases the effect of the tricyclic agent (source: Drug Bank) |
| vecuronium |
|
The quinine derivative increases the effect of the muscle relaxant (source: Drug Bank) |
| verapamil |
|
Verapamil increases the effect of quinidine (source: Drug Bank) |
| voriconazole |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| warfarin |
|
Quinine/quinidine increases the anticoagulant effect (source: Drug Bank) |
| ziprasidone |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
- Drug-Induced Long QT Intervals




- PD
Submitted by Dan Roden, MD involving ADRB1, ADRB2, KCNE1, KCNE2, KCNH2, KCNQ1, SCN5A, almokalant, amiodarone, amitriptyline, bretylium, bupivacaine, cisapride, disopyramide, dofetilide, encainide, fluconazole, haloperidol, hydroquinidine, isoflurane, itraconazole, ketoconazole, lithium, loratadine, metoclopramide, nortriptyline, procainamide, quinidine, sematilide, sotalol, sulfamethoxazole, thioridazine, trimethoprim, , Long QT Syndrome, Proarrhythmia and Torsades de Pointes - SLC22A2 Functional Protein Variants




- FA
Submitted by Kathleen M. Giacomini, PhD involving SLC22A2, , cimetidine, metformin, MPP+, phenformin, procainamide and quinidine - Xenopus expression of variant SLC22A2 proteins




- FA
Submitted by Kathleen M. Giacomini, PhD involving SLC22A2, , metformin, MPP+, phenformin, procainamide and quinidine
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
- Genetic Associations in Drug-induced QT Prolongation and Torsades
- Measured and Predicted Changes in QT Intervals During Atrial Fibrillation
- OCTN1 Phenotype
- Physicochemical determinants of human renal clearance
- The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
